Further questions that stem from KEYNOTE-811 include what the best approach for PDL1-negative tumours will be, whether or not chemotherapy can be de-escalated whilst maintaining survival efficacy, and the best approach for HER2-directed treatment with the expansion of ADCs, such as T-DXd, in the oncology landscape. This evidence concerns the gene ERBB2 and neoplasm.